Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:44 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
NCT00522990 · Astex Pharmaceuticals, Inc. · PHASE1/PHASE2 · terminated · last registry update 2024-08-02 · Childhood acute lymphoblastic leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Recommended Phase II dose determined” | – | Registry record, Astex Pharmaceuticals, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ABL1 in childhood acute lymphoblastic leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-06-12Results posted on the registry: Dana-Farber Cancer Institute, Doxorubicin + Cytarabine (NCT00476190)
- 2025-06-08Also stopped (terminated): M.D. Anderson Cancer Center, Cyclophosphamide + Cytarabine (NCT02420717)
- 2025-05-08Results posted on the registry: M.D. Anderson Cancer Center, Dexamethasone + Ponatinib Hydrochloride (NCT03576547)
- 2025-05-08Also stopped (terminated): M.D. Anderson Cancer Center, Dexamethasone + Ponatinib Hydrochloride (NCT03576547)
- 2025-03-06Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Randomization + Blinatumomab + chemotherapy + Randomization + Isatuximab + Standard frontline T-ALL chemotherapy backbone (NCT06860269)
- 2025-03-04Phase 3 first posted: Institute of Hematology & Blood Diseases Hospital, China, Venetoclax + Dasatinib (NCT06855810)
- 2025-02-17Results posted on the registry: M.D. Anderson Cancer Center, Cyclophosphamide + Cytarabine (NCT00390793)
- 2025-01-15Results posted on the registry: Takeda, Ponatinib + Chemotherapy Agents (NCT04501614)
- 2024-03-12Results posted on the registry: National Cancer Institute (NCI), Clofarabine + Cyclophosphamide (NCT02883049)
- 2023-10-27Results posted on the registry: Takeda, Ponatinib + Imatinib (NCT03589326)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision